Kura Q3 10-Q: $13.9M KOMZIFTI Quarter, $492.1M Cash, New $275M Oberland Facility
KURA is trading near its 52-week low of $6.75 (6.7% above the low).
Summary
Kura's Q3 10-Q confirms $13.9 million of KOMZIFTI revenue and $492.1 million in cash, and discloses a new $275.0 million Oberland debt facility plus a ziftomenib royalty agreement signed November 9, 2026.
Key Events · Earnings and Guidance · KURA
-
KOMZIFTI Revenue Reaches $13.9M
Q3 2026 net product revenue was $13.9 million versus $9.1 million in Q2, and $28.8 million for the first nine months of 2026.
-
Cash of $492.1M at Quarter End
Cash, cash equivalents and short-term investments totaled $492.1 million at September 30, 2026, down from $667.2 million at December 31, 2025; management says this funds operations into 2028.
-
New $275M Oberland Facility, $50M Drawn
On November 9, 2026, Kura borrowed $50.0 million under a facility allowing up to $275.0 million across five tranches, with a $50.0 million tranche tied to positive KOMET-017 Phase 3 data, and repaid Hercules (~$11.6 million).
-
Ziftomenib Royalty Pledged to Oberland
A royalty participation agreement requires quarterly single-digit royalties on U.S. ziftomenib net sales from October 1, 2028, capped at 20.0% of principal funded, running to November 9, 2036 at the latest.
Analysis · KURA · Life Sciences
The headline numbers were already out this evening, but the 10-Q adds the full balance sheet and, more importantly, the financing architecture behind the runway claim. On November 9, 2026, Kura closed a $275.0 million Oberland term loan, drew $50.0 million, and repaid Hercules. In exchange, it gave up a royalty on U.S. ziftomenib sales starting October 2028, capped at 20% of principal funded, and sold TPC 687,758 shares at $7.27 with up to $25.0 million more committed. Cash of $492.1 million plus $180.0 million of expected Kyowa Kirin milestones is what management says funds operations past the 2028 KOMET-017 readout. The quarter itself was clean on the top line — $13.9 million of KOMZIFTI revenue, up from $9.1 million — while R&D held flat at $66.9 million and the net loss narrowed to $70.2 million from $74.1 million a year ago. The Caspian spinout nets to zero in the P&L: a $30.6 million deconsolidation gain offset by a $30.6 million equity-method loss.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KURA was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.4M. The 52-week trading range was $6.75 to $13.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.